NIKKEI 225
38,229.11 -44.99 (-0.12%) HANG SENG
18,963.68 +487.78 (+2.64%) CRUDE OIL
78.00 -0.26 (-0.33%) GOLD FUTURES
2,367.40 -7.60 (-0.32%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
48,982.80 +351.58 (+0.72%)
BDTX May 2024 7.500 call
| Previous close | 0.6000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 122 |
ZacksShould You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlobeNewswireBlack Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025Presented real world evidence on the evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 across multiple lines of therapy at the 2024 AACR annual meetingPoster presentations upcoming June 1st at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-escala
- GlobeNewswire
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL. The two poster presentations describe data for BDTX-1535 in patients with recurrent glioblastoma (GBM) across two clinical trials: a Phase 1
